NAMS Menopause Certification ACTUAL EXAM 2026/2027 | 2
Versions | Real Test Bank | Evidence-Based | Pass
Guaranteed - A+ Graded
VERSION A: 100 Questions
Section 1: Physiology of Menopause and Reproductive Aging (17 Questions)
Q1-A: A 48-year-old patient reports irregular menstrual cycles with variable flow for the
past 8 months. Her FSH level is 28 IU/L (elevated but not menopausal) and estradiol is
45 pg/mL. According to STRAW+10 staging criteria, which reproductive aging stage
best describes her status?
A. Late reproductive phase (peak fertility)
B. Early menopausal transition [CORRECT]
C. Late menopausal transition
D. Postmenopause
Correct Answer: B
Rationale: According to STRAW+10 (Stages of Reproductive Aging Workshop +10 years)
criteria, the early menopausal transition is characterized by increased variability in
menstrual cycle length (difference of >7 days between consecutive cycles), elevated
FSH (>25 IU/L but variable), and normal or slightly decreased estradiol. The late
menopausal transition (C) is defined by ≥2 skipped cycles and amenorrhea of ≥60 days.
Postmenopause (D) requires 12 months of amenorrhea. Late reproductive phase (A)
shows subtle changes in cycle length but FSH typically <20 IU/L. The variable FSH and
cycle irregularity with maintained estradiol production place this patient in early
transition.
,Q2-A: Which hormonal change is the primary driver of vasomotor symptoms during the
menopausal transition?
A. Absolute deficiency of estradiol
B. Fluctuations in estradiol levels with narrowing of the hypothalamic thermoneutral
zone [CORRECT]
C. Elevated progesterone levels
D. Decreased FSH secretion
Correct Answer: B
Rationale: Vasomotor symptoms (VMS) are driven primarily by the narrowing of the
hypothalamic thermoneutral zone due to fluctuating (not absolutely low) estradiol levels
that occur during the menopausal transition. This neuroendocrine instability causes
inappropriate heat dissipation responses (hot flashes) to minimal core body
temperature elevations. The thermoregulatory center in the preoptic area becomes
more sensitive to neurotransmitters (norepinephrine, serotonin). Absolute deficiency (A)
occurs postmenopause when VMS typically decline. Progesterone (C) decreases during
transition. FSH (D) rises, not falls, in response to decreased negative feedback.
Q3-A: A 52-year-old patient with 14 months of amenorrhea has FSH 85 IU/L and
estradiol <10 pg/mL. Which metabolic consequence is most directly attributable to her
ovarian status?
A. Increased insulin sensitivity
B. Decreased LDL receptor activity leading to atherogenic lipid profile [CORRECT]
C. Enhanced bone formation exceeding resorption
D. Decreased visceral adiposity
Correct Answer: B
,Rationale: Postmenopausal estrogen deficiency results in decreased hepatic LDL
receptor activity and increased hepatic lipase activity, producing an atherogenic lipid
profile characterized by increased LDL, decreased HDL, and increased triglycerides.
Estrogen normally upregulates LDL receptors and suppresses hepatic lipase. Insulin
sensitivity decreases (A, not increases) due to visceral fat accumulation. Bone
resorption exceeds formation (C, opposite) leading to osteoporosis. Visceral adiposity
increases (D, not decreases) due to androgenic shift in fat distribution.
Q4-A: Which neurotransmitter system is most directly involved in the pathophysiology of
genitourinary syndrome of menopause (GSM)?
A. Dopaminergic pathways in the basal ganglia
B. Cholinergic pathways in the bladder detrusor
C. Estrogen-mediated effects on collagen synthesis and blood flow in urogenital tissues
[CORRECT]
D. Serotonergic pathways in the raphe nuclei
Correct Answer: C
Rationale: GSM results from estrogen deficiency causing atrophy of estrogen-sensitive
urogenital tissues (vulva, vagina, urethra, bladder trigone). Estrogen maintains collagen
content, elasticity, blood flow, and glycogen production (supporting lactobacilli and
acidic pH). Specific mechanisms include: decreased Type I and III collagen, reduced
vascularization, thinning of epithelium, and loss of rugae. While cholinergic pathways
(B) affect bladder contraction and serotonin (D) affects mood/pain, the primary GSM
pathophysiology is local estrogen deficiency affecting tissue structure. Dopamine (A) is
not central to GSM.
Q5-A: According to the "timing hypothesis," which patient characteristic is associated
with potential cardiovascular benefit from menopausal hormone therapy?
, A. Age >65 years with established coronary disease
B. Initiation within 10 years of menopause or age <60 years [CORRECT]
C. Presence of multiple cardiovascular risk factors regardless of age
D. History of venous thromboembolism
Correct Answer: B
Rationale: The timing hypothesis, supported by WHI subgroup analyses, KEEPS, and
ELITE trials, suggests that menopausal hormone therapy (MHT) initiated within 10 years
of menopause onset or before age 60 may slow atherosclerosis progression and reduce
coronary events. This "window of opportunity" reflects healthier vascular endothelium
responsive to estrogen's vasoprotective effects (enhanced NO production, antioxidant
effects). Starting MHT >10 years postmenopause or after age 60 (A) may expose
established plaque to pro-thrombotic/pro-inflammatory effects. Risk factors alone (C)
or VTE history (D) are not indications for cardioprotection.
Q6-A: Which marker most accurately reflects the decline in ovarian follicular reserve
during reproductive aging?
A. Inhibin B [CORRECT]
B. Activin A
C. Müllerian inhibiting substance (MIS)
D. Prolactin
Correct Answer: A
Rationale: Inhibin B, produced by granulosa cells of developing follicles, is the most
sensitive marker of ovarian reserve decline. It provides negative feedback to pituitary
FSH secretion. As follicular numbers decrease, inhibin B falls, allowing FSH to rise
(earliest endocrine change in reproductive aging). Inhibin A rises in late transition.
Activin A (B) increases but less specific. MIS/AMH (C) reflects follicle pool but is
Versions | Real Test Bank | Evidence-Based | Pass
Guaranteed - A+ Graded
VERSION A: 100 Questions
Section 1: Physiology of Menopause and Reproductive Aging (17 Questions)
Q1-A: A 48-year-old patient reports irregular menstrual cycles with variable flow for the
past 8 months. Her FSH level is 28 IU/L (elevated but not menopausal) and estradiol is
45 pg/mL. According to STRAW+10 staging criteria, which reproductive aging stage
best describes her status?
A. Late reproductive phase (peak fertility)
B. Early menopausal transition [CORRECT]
C. Late menopausal transition
D. Postmenopause
Correct Answer: B
Rationale: According to STRAW+10 (Stages of Reproductive Aging Workshop +10 years)
criteria, the early menopausal transition is characterized by increased variability in
menstrual cycle length (difference of >7 days between consecutive cycles), elevated
FSH (>25 IU/L but variable), and normal or slightly decreased estradiol. The late
menopausal transition (C) is defined by ≥2 skipped cycles and amenorrhea of ≥60 days.
Postmenopause (D) requires 12 months of amenorrhea. Late reproductive phase (A)
shows subtle changes in cycle length but FSH typically <20 IU/L. The variable FSH and
cycle irregularity with maintained estradiol production place this patient in early
transition.
,Q2-A: Which hormonal change is the primary driver of vasomotor symptoms during the
menopausal transition?
A. Absolute deficiency of estradiol
B. Fluctuations in estradiol levels with narrowing of the hypothalamic thermoneutral
zone [CORRECT]
C. Elevated progesterone levels
D. Decreased FSH secretion
Correct Answer: B
Rationale: Vasomotor symptoms (VMS) are driven primarily by the narrowing of the
hypothalamic thermoneutral zone due to fluctuating (not absolutely low) estradiol levels
that occur during the menopausal transition. This neuroendocrine instability causes
inappropriate heat dissipation responses (hot flashes) to minimal core body
temperature elevations. The thermoregulatory center in the preoptic area becomes
more sensitive to neurotransmitters (norepinephrine, serotonin). Absolute deficiency (A)
occurs postmenopause when VMS typically decline. Progesterone (C) decreases during
transition. FSH (D) rises, not falls, in response to decreased negative feedback.
Q3-A: A 52-year-old patient with 14 months of amenorrhea has FSH 85 IU/L and
estradiol <10 pg/mL. Which metabolic consequence is most directly attributable to her
ovarian status?
A. Increased insulin sensitivity
B. Decreased LDL receptor activity leading to atherogenic lipid profile [CORRECT]
C. Enhanced bone formation exceeding resorption
D. Decreased visceral adiposity
Correct Answer: B
,Rationale: Postmenopausal estrogen deficiency results in decreased hepatic LDL
receptor activity and increased hepatic lipase activity, producing an atherogenic lipid
profile characterized by increased LDL, decreased HDL, and increased triglycerides.
Estrogen normally upregulates LDL receptors and suppresses hepatic lipase. Insulin
sensitivity decreases (A, not increases) due to visceral fat accumulation. Bone
resorption exceeds formation (C, opposite) leading to osteoporosis. Visceral adiposity
increases (D, not decreases) due to androgenic shift in fat distribution.
Q4-A: Which neurotransmitter system is most directly involved in the pathophysiology of
genitourinary syndrome of menopause (GSM)?
A. Dopaminergic pathways in the basal ganglia
B. Cholinergic pathways in the bladder detrusor
C. Estrogen-mediated effects on collagen synthesis and blood flow in urogenital tissues
[CORRECT]
D. Serotonergic pathways in the raphe nuclei
Correct Answer: C
Rationale: GSM results from estrogen deficiency causing atrophy of estrogen-sensitive
urogenital tissues (vulva, vagina, urethra, bladder trigone). Estrogen maintains collagen
content, elasticity, blood flow, and glycogen production (supporting lactobacilli and
acidic pH). Specific mechanisms include: decreased Type I and III collagen, reduced
vascularization, thinning of epithelium, and loss of rugae. While cholinergic pathways
(B) affect bladder contraction and serotonin (D) affects mood/pain, the primary GSM
pathophysiology is local estrogen deficiency affecting tissue structure. Dopamine (A) is
not central to GSM.
Q5-A: According to the "timing hypothesis," which patient characteristic is associated
with potential cardiovascular benefit from menopausal hormone therapy?
, A. Age >65 years with established coronary disease
B. Initiation within 10 years of menopause or age <60 years [CORRECT]
C. Presence of multiple cardiovascular risk factors regardless of age
D. History of venous thromboembolism
Correct Answer: B
Rationale: The timing hypothesis, supported by WHI subgroup analyses, KEEPS, and
ELITE trials, suggests that menopausal hormone therapy (MHT) initiated within 10 years
of menopause onset or before age 60 may slow atherosclerosis progression and reduce
coronary events. This "window of opportunity" reflects healthier vascular endothelium
responsive to estrogen's vasoprotective effects (enhanced NO production, antioxidant
effects). Starting MHT >10 years postmenopause or after age 60 (A) may expose
established plaque to pro-thrombotic/pro-inflammatory effects. Risk factors alone (C)
or VTE history (D) are not indications for cardioprotection.
Q6-A: Which marker most accurately reflects the decline in ovarian follicular reserve
during reproductive aging?
A. Inhibin B [CORRECT]
B. Activin A
C. Müllerian inhibiting substance (MIS)
D. Prolactin
Correct Answer: A
Rationale: Inhibin B, produced by granulosa cells of developing follicles, is the most
sensitive marker of ovarian reserve decline. It provides negative feedback to pituitary
FSH secretion. As follicular numbers decrease, inhibin B falls, allowing FSH to rise
(earliest endocrine change in reproductive aging). Inhibin A rises in late transition.
Activin A (B) increases but less specific. MIS/AMH (C) reflects follicle pool but is
